Predictive Oncology Inc. (S1K.F)
| Previous Close | 4.0000 |
| Open | N/A |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | N/A - N/A |
| 52 Week Range | 4.0000 - 9.3200 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 0 |
| Beta (5Y Monthly) | 1.40 |
| PE Ratio (TTM) | -0.00 |
| EPS (TTM) | -6.0900 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswirePredictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update
Company to host investor call and webcast today, May 15th, at 8:30am EDTPITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2024, and pro
- GlobeNewswire
Predictive Oncology to Report First Quarter 2024 Financial Results on Wednesday, May 15, 2024
Management to host conference call and webcast at 8:30am ETPITTSBURGH, May 10, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it w
- GlobeNewswire
Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
PITTSBURGH, April 30, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market, as part of a $6.2 million Phase 2B grant awarded by the United States Department of Defense (DoD). “Predictive Oncology will play a critical role in helping to make our M2SR flu vaccine more stable and sustainable as we advance our clinical trials,” says Paul
